Table 4.

Multivariable logistic regression of factors associated with IGT in all HIV-infected and control participants

	HIV+ subjects (n = 491)			Control subjects (n = 187)
	OR	95% CI	P value	OR	95% CI	P value
Female vs. male	0.61	(0.28–1.32)	0.21	3.39	(0.87–13.12)	0.077
African American vs. white	1.04	(0.58–1.87)	0.90	1.54	(0.60–3.97)	0.37
Other vs. white	1.27	(0.58–2.77)	0.55
Age (per decade)	1.73	(1.28–2.35)	0.0003	0.59	(0.16–2.19)	0.43
Drinks
<1 vs. none	0.88	(0.47–1.65)	0.69	0.26	(0.06–1.06)	0.060
1–7 vs. none	0.69	(0.37–1.28)	0.24	0.27	(0.07–1.03)	0.056
>7 vs. none	0.37	(0.15–0.90)	0.028	0.83	(0.20–3.40)	0.80
Physical activity
2nd vs. 1st quartile	1.51	(0.82–2.78)	0.18	2.08	(0.50–8.77)	0.32
3rd vs. 1st quartile	1.57	(0.82–3.03)	0.17	1.60	(0.43–5.91)	0.48
4th vs. 1st quartile	0.41	(0.18–0.97)	0.042	1.17	(0.25–5.45)	0.84
Upper trunk SAT (doubling)	2.11	(1.43–3.12)	0.0002	3.56	(1.41–8.97)	0.0069
Leg SAT (doubling)	0.57	(0.36–0.91)	0.018	0.17	(0.05–0.62)	0.0069
Pertinent negatives
VAT (doubling)	1.16	(0.85–1.58)	0.35	2.85	(0.90–9.01)	0.070
VAT-to-abdominal fat ratio (doubling)	1.19	(0.78–1.84)	0.42	3.41	(0.62–18.7)	0.14
Current vs. never smoking	1.07	(0.61–1.91)	0.81	1.43	(0.37–5.54)	0.61
Past vs. never smoking	0.65	(0.34–1.23)	0.19	1.57	(0.44–5.56)	0.49
Tenofovir use	0.75	(0.45–1.23)	0.25

P values in boldface denote statistical significance at P < 0.05. IGT is defined as 2-h glucose >140 mg/dL. Unselected factors (pertinent negatives) are in italics; values shown are those that would result if the factors were added back to the model individually. Those with fasting glucose ≥126 mg/dL or taking diabetes medication are excluded. Separate models were constructed for HIV-infected and control participants. OR, odds ratio.